

**RECEIVED
CENTRAL FAX CENTER**

Attorney Docket No.: 4341.224-US
 Application No.: 10/620,651
 Filed: July 16, 2003
 Applicants: Jan Markussen et al.
 Via Facsimile : 571-273-8300

NOV 27 2006

Attorney Docket No.: 4341.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jan Markussen et. al. Confirmation No. 1417

Application No.: 10/620,651 Group Art Unit: 1646

Filed: July 16, 2003 Examiner: Chandra, Gyan

For: Insulin Derivatives

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on December 19, 1997, Reel 008872, Frame 0407).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,251,856, issued June 26, 2001,
 is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

U.S. Patent No. 6,251,856, issued June 26, 2001,

RECEIVED
CENTRAL FAX CENTER

Attorney Docket No.: 4341.224-US
Application No.: 10/620,651
Filed: July 16, 2003
Applicants: Jan Markussen et al.
Via Facsimile : 571-273-8300

NOV 27 2006

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,251,856, issued June 26, 2001,

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 27, 2006

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

**RECEIVED
CENTRAL FAX CENTER**

Attorney Docket No.: 4341.224-US
Application No.: 10/620,651
Filed: July 16, 2003
Applicants: Jan Markussen et al.
Via Facsimile : 571-273-8300

NOV 27 2006

Attorney Docket No.: 4341.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jan Markussen et. al. Confirmation No. 1417

Application No.: 10/620,651 Group Art Unit: 1646

Filed: July 16, 2003 Examiner: Chandra, Gyan

For: Insulin Derivatives

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir.

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on December 19, 1997, Reel 008872, Frame 0407).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,251,856, issued June 26, 2001,
is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

U.S. Patent No. 6,251,856, issued June 26, 2001,

RECEIVED
CENTRAL FAX CENTER

Attorney Docket No.: 4341.224-US
Application No.: 10/620,651
Filed: July 16, 2003
Applicants: Jan Markussen et al.
Via Facsimile : 571-273-8300

NOV 27 2006

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,251,856, issued June 26, 2001,

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 27, 2006

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE